CSL LIMITED(CSL.AU)近日宣布,其针对Andembry®(Garadacimab-Gxii)在儿童遗传性血管性水肿(HAE)患者中开展的IIIb期临床研究,取得了积极的顶线结果。这些数据将有力支持该公司计划中的扩大儿科适应症申报工作。
CSL LIMITED(CSL.AU)近日宣布,其针对Andembry®(Garadacimab-Gxii)在儿童遗传性血管性水肿(HAE)患者中开展的IIIb期临床研究,取得了积极的顶线结果。这些数据将有力支持该公司计划中的扩大儿科适应症申报工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.